↓ Skip to main content

CD38 as a PET Imaging Target in Lung Cancer

Overview of attention for article published in Molecular Pharmaceutics, June 2017

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

twitter
4 X users

Readers on

mendeley
33 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
CD38 as a PET Imaging Target in Lung Cancer
Published in
Molecular Pharmaceutics, June 2017
DOI 10.1021/acs.molpharmaceut.7b00298
Pubmed ID
Authors
Abstract

Daratumumab (Darzalex®, Janssen Biotech) is a clinically-approved antibody targeting CD38 for the treatment of multiple myeloma. However, CD38 is also expressed by other cancer cell types, including lung cancer, where its expression or absence may offer prognostic value. We therefore developed a PET tracer based upon daratumumab for tracking CD38 expression, utilizing murine models of non-small cell lung cancer to verify its specificity. Daratumumab was prepared for radiolabeling with (89)Zr (t1/2 = 78.4 h) through conjugation with desferrioxamine (Df). Western blot, flow cytometry, and saturation binding assays were utilized to characterize CD38 expression and binding of daratumumab to three non-small cell lung cancer cell lines: A549, H460, and H358. Murine xenograft models of the cell lines were also generated for further in vivo studies. Longitudinal PET imaging was performed following injection of (89)Zr-Df-daratumumab out to 120 h post-injection, and nonspecific uptake was also evaluated through the injection of a radiolabeled control IgG antibody in A549 mice, (89)Zr-Df-IgG. Ex vivo biodistribution and histological analyses were also performed after the terminal imaging timepoint at 120 h post-injection. Through cellular studies, A549 cells were found to express higher levels of CD38 than the H460 or H358 cell lines. PET imaging and ex vivo biodistribution studies verified in vitro trends, with A549 tumor uptake peaking at 8.1 ± 1.2 %ID/g at 120 h post-injection according to PET analysis, and H460 and H358 at lower levels at the same timepoint (6.7 ± 0.7 %ID/g and 5.1 ± 0.4 %ID/g, respectively; n = 3-4). Injection of a non-specific radiolabeled IgG into A549 tumor-bearing mice also demonstrated lower tracer uptake of 4.4 ± 1.3 %ID/g at 120 h. Immunofluorescent staining of tumor tissues showed higher staining levels present in A549 tissues over H460 and H358. Thus, (89)Zr-Df-daratumumab is able to image CD38-expressing tissues in vivo using PET, as verified through the exploration of non-small cell lung cancer models in this study. This agent therefore holds potential to image CD38 in other malignancies and aid in patient stratification and elucidation of the biodistribution of CD38.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 33 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 33 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Researcher 6 18%
Student > Bachelor 5 15%
Student > Ph. D. Student 4 12%
Student > Postgraduate 3 9%
Other 1 3%
Other 3 9%
Unknown 11 33%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 10 30%
Biochemistry, Genetics and Molecular Biology 6 18%
Chemistry 4 12%
Pharmacology, Toxicology and Pharmaceutical Science 2 6%
Agricultural and Biological Sciences 1 3%
Other 0 0%
Unknown 10 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 June 2017.
All research outputs
#14,350,775
of 22,979,862 outputs
Outputs from Molecular Pharmaceutics
#1,965
of 4,144 outputs
Outputs of similar age
#177,050
of 317,335 outputs
Outputs of similar age from Molecular Pharmaceutics
#26
of 79 outputs
Altmetric has tracked 22,979,862 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,144 research outputs from this source. They receive a mean Attention Score of 4.6. This one is in the 48th percentile – i.e., 48% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,335 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 79 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.